Background: Serum Golgi protein 73 (GP73) is a promising biomarker of liver fibrosis, but most data are from hepatitis B virus-related liver diseases rather than hepatitis C virus (HCV). Objective: To evaluate the use of GP73 as a marker for liver fibrosis in chronic HCV patients and to correlate it with fibrosis staging of liver biopsy and other laboratory findings. Subjects and Methods: The study included 37 chronic HCV patients who were subdivided according to liver biopsy results into chronic HCV patients without fibrosis (10) and chronic HCV patients with fibrosis (27). 37 healthy individuals were taken as control. All participants were subjected to determination of liver function tests with calculation of AST-to-Platelet Ratio Index (APRI) and serum GP73 by ELISA. Results: GP73 was significantly increased in chronic HCV patients with fibrosis when compared to patients without fibrosis and healthy control. A significant positive correlation was observed between GP73 and advanced liver function tests, increased fibrosis stage and APRI in chronic HCV patients with fibrosis. Based on receiver operating characteristic (ROC) curve analysis, GP73 had an area under curve (AUC) of 0.909 with 81.8% sensitivity and 93.3% specificity for prediction of significant fibrosis. On combination with APRI, the sensitivity was increased to 90.9%. Conclusion: GP73 can be used as serum marker for prediction of significant liver fibrosis in chronic HCV patients either alone or in combination with APRI. It can be also useful in monitoring fibrosis progression.